[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
March 27, 1995

Pamidronate for Cancer-Associated Hypercalcemia

Author Affiliations

Boston, Mass

Arch Intern Med. 1995;155(6):641-642. doi:10.1001/archinte.1995.00430060105015

The article by Gucalp and colleagues,1 comparing rapid and slow intravenous infusion regimens of pamidronate in the treatment of malignancy-associated hypercalcemia, was interesting and informative. In this context, I would like to draw the authors' attention to some further data concerning this subject.

The authors took into account several laboratory parameters in the randomized groups of patients receiving either a 4- or 24-hour infusion of 60 mg of pamidronate. Two other parameters have, however, also been shown to affect the response of tumor-induced hypercalcemia to pamidronate. Gurney and associates2 showed that the concentration of parathyroid hormone-related protein is an important predictor of this response. An undetectable level of parathyroid hormone-related protein (<2 pmol/L) was associated with normalization of the serum calcium concentration in seven of seven patients, and the levels of 2 to 12 pmol/L were associated with a similar response in 10 of 14 patients, while the